Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5542 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 18 19 20 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Strüngmann Group–MC Services: public relations, 201602 service existent for AiCuris Anti-infective Cures GmbH 2016-02-18
Transcend Medical–Novartis: investment, 201602 acquisition €na by Alcon 2016-02-18
Ipsen–3B Pharmaceuticals: radiopharmaceutical, 201602– license ww excl for radiopharmaceuticals in oncology 2016-02-17
Saphetor–Capricorn One: public relations, 201602 service existent for Saphetor SA 2016-02-17
Saphetor–SEVERAL: investment, 201602 seed financing round CHF1.2m from undisclosed investors 2016-02-17
Venture Valuation–Nasdaq OMX: press release distribution, 201602– collab integration of channel news in Biotechgate online directories 2016-02-17
Apogenix–Germany (govt): grant, 201602 BMBF grant €3m for developm of companion diagnostic w R-Biopharm for APG101 in glioblastoma 2016-02-16
Merck (DE)–Weizmann Institute: life sciences, 201602– collab 3y framework agreement research 2016-02-16
Novartis–Pfizer: biosimilar, 201602– Sandoz acquires rights to PF-06438179 (infliximab) in EEA which Pfizer had to divest after Hospira acquisition 2016-02-12
Curetis–Degroof Petercam: financial services, 201602– supply service liquidity provider to facilitate share trading on Euronext Brussels + Amsterdam 2016-02-11
Armo BioSciences–HBM: investment, 201602 private financing round Series C totalling $50m incl $10m from new investor HBM Healthcare Investments 2016-02-10
Armo BioSciences–SEVERAL: investment, 201602 private financing round Series C $50m from existent + new investors 2016-02-10
Hemovent–SEVERAL: investment, 201602 financing round Series A $6m led by MIG Verwaltungs AG 2016-02-10
Qiagen–10x Genomics: genomic technology, 201602– collab co-developm + co-marketing of NGS + single-cell biology + bioinformatics solutions 2016-02-09
Sophia Genetics–Swift Biosciences: molecular diagnostics, 201602– collab product integration offering combined MDx solutions in Europe 2016-02-09
Tollys–Riboxx: cancer drug, 201602– license ww excl to Apoxxim TLR3-ligand programme to Tollys 2016-02-04
Univ Rochester–Indivumed: tissue bank, 201602– collab 3y €na to establish UMRC-Indivumed tissue bank for cancer research 2016-02-04
Labiotech.eu–SEVERAL: investment, 201602 seed financing round €6-digit led by WestTech Ventures 2016-02-03
SmartDyeLivery–SEVERAL: investment, 201602 seed financing from bm|t + Sparkasse Jena-Saale-Holzland 2016-02-03
Syngenta–ChemChina: investment, 201602– recommended cash acquisition offer valuing Syngenta at over $43b ANNOUNCED 2016-02-03
Evotec–Michael J Fox Foundation: grant, 201602 research grant for further developm of TargetaSN programme to treat Parkinson’s disease 2016-02-02
Medicxi Ventures–SEVERAL: investment, 201602 closing €210m of MV1 fund incl investments from GSK + JnJ Innovation JJDC 2016-02-02
Mission Therapeutics–Roche: investment, 201602 financing round totalling £60m incl returning co-investor Roche Venture Fund 2016-02-02
Mission Therapeutics–SEVERAL: investment, 201602 financing round £60m led by Imperial Innovations + new investor Woodford PCT 2016-02-02
Qiagen–CosmosID: bioinformatics, 201602– collab integration of CosmosID metagenomics analysis platform in CLC Genomics Workbench 2016-02-02
Alere–Abbott: investment, 201602– acquisition $5.8b equity value with $56/share ANNOUNCED 2016-02-01
InflaRx–MC Services: public relations, 201601 service existent by MC Services AG 2016-01-28
Medigene–Univ Lausanne: TCR technology, 201601– collab €na service by UNIL using NTAmer technology of TCMetrix 2016-01-25
Merck (US)–Affimed: cancer immunotherapy, 201601– collab €na clinical research combining AFM13 w pembrolizumab in Hodgkin lymphoma 2016-01-25
SeNostic–SEVERAL: investment, 201601 seed financing round led by HTGF 2016-01-25
RA-MAP Consortium–Protagen: biomarker discovery, 201601– collab Protagen joins RA-MAP Consortium contributing SeroTag platform for RA biomarker search 2016-01-21
Synoste–Evonik: investment, 201601 financing round Series A single-digit €n from Evonik + HTGF + Finnvera + Lifeline Ventures + business angels 2016-01-21
Synoste–High-Tech Gründerfonds: investment, 201601 financing round Series A single-digit €m from Evonik + HTGF + Finnvera + Lifeline Ventures + angels 2016-01-21
Synoste–SEVERAL: investment, 201601 financing round Series A single-digit €n from Evonik + HTGF + Finnvera + Lifeline Ventures + business angels 2016-01-21
Vasopharm–Hume Brophy: public relations, 201601 service existent by Hume Brophy 2016-01-21
Vasopharm–SEVERAL: investment, 201601 financing round €20m led by HeidelbergCapital + Entrepreneurs Fund + Fort Rock Capital 2016-01-21
City of Hope–Cevec: rec protein production technology, 201601– license €na to CAP GT technology to Beckman Research Institute 2016-01-20
PharmGenomics (DE)–SEVERAL: investment, 201601 financing round incl ISB + KfW + private investors 2016-01-20
Abviris–High-Tech Gründerfonds: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Abviris–Schleswig-Holstein (govt): investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Abviris–SEVERAL: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein 2016-01-19
Zespri–Metabolomic Discoveries: metabolomic services, 201601– supply service MS-based profiling of kiwi fruit using Flavour Profiler Technology 2016-01-18
Emerald Cleantech–Evonik: investment, 201601 existent investment in Emerald Cleantech Fund III by Evonik Venturing 2016-01-15
GRC SinoGreen–Evonik: investment, 201601 investment €na in GRC SinoGreen Fund III by Evonik Venturing 2016-01-15
Pangaea Ventures–Evonik: investment, 201601 existent investment in Pangaea Ventures Fund III by Evonik Venturing 2016-01-15
Ayoxxa–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
Pepperprint–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
Personal MedSystems–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
Sonormed–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme 2016-01-13
HRTBT Medical Solutions–DocCheck: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano 2016-01-12
HRTBT Medical Solutions–High-Tech Gründerfonds: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano 2016-01-12
HRTBT Medical Solutions–SEVERAL: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano 2016-01-12
AB2 Bio–SEVERAL: investment, 201601 financing round Series B CHF21m ($21m) from existent + new investors 2016-01-11
AbVitro–Juno Therapeutics: investment, 201601 acquisition $78m in cash + 1.289m shares of Juno stock 2016-01-11
Array BioPharma–Qiagen: molecular companion diagnostics, 201601– collab master agreement developm + commercialisation of CDx for drugs 2016-01-11
Nestlé–Seres Therapeutics: microbiome-based drug, 201601– ww rights excl North America to SER-109+SER-262+SER-287 $120m upfront 2016-01-11
Novartis–Surface Oncology: cancer immunotherapy, 201601– collab + license up to $170m in upfront + equity + milestones for 4 pre-clinical programs 2016-01-11
Novimmune–SEVERAL: investment, 201601 financing round CHF30m from existing shareholders 2016-01-11
Tensha Therapeutics–Roche: investment, 201601– acquisition $115m upfront cash + $420m milestones 2016-01-11
Affymetrix–Thermo Fisher: investment, 201601–201603 acquisition of Affymetrix for $1.3b in cash 2016-01-08
Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix 2016-01-07
C4 Therapeutics–Roche: investment, 201601 financing round Series A totalling $73m incl lead investor Cobro Ventures + co-investor Roche 2016-01-07
C4 Therapeutics–SEVERAL: investment, 201601 financing round Series A $73m led by Cobro plus Cormorant + Kraft Group + EG Capital + Roche + Novartis 2016-01-07
Merck (DE)–Biocartis: molecular companion diagnostics, 201601– collab developm liquid biopsy Idylla RAS test RUO for mCRC 2016-01-07
Roche–C4 Therapeutics: drug discovery, 201601– collab up to >750m developm TPD therapeutics against Roche targets using Degronimid platform 2016-01-07
Biogen–Rodin Therapeutics: CNS drugs, 201601– collab multi-year around neural epigenetics incl investment by Biogen 2016-01-06
Rodin Therapeutics–SEVERAL: investment, 201601– preferred stock financing commitments totalling $17.3m from Altas Venture + Biogen 2016-01-06
BRAIN–MIG Fonds: investment, 201601 existent shareholding of 20% by MIG 2016-01-05
BRAIN–Oddo: investment banking, 201601– supply service Oddo Seydler is lead manager for IPO of BRAIN at FSE 2016-01-05
BRAIN–Putsch (Recaro): investment, 201601 existent shareholding of 51% by MP Betiligungs GmbH 2016-01-05
BRAIN–SEVERAL: investment, 201601–201602 IPO €32.5m net €31.5m w 3.5m+108k shares at €9/share at Frankfurt Stock Exchange 2016-01-05
Scholar Rock–SEVERAL: investment, 201601 financing round Series B $36m 2016-01-04
Famille Michaud Apiculteurs–Bruker Corp: NMR FoodScreener, 201601– supply use of Honey-Profiling module of NMR FoodScreener for QC of honey 2016-01-01
Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG 2016-01-01
MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems 2016-01-01
Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program 2016-01-01
Roche–Max Planck: drug discovery services, 201601–20812 collab LDC will act as translational incubator for small molecule projects w academic partners 2016-01-01
Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets 2016-01-01
UCB–Evotec: compound management, 201601–202012 supply service €na sample management for UCB by Evotec Toulouse 2016-01-01
Mo Bio Laboratories–Qiagen: investment, 2015Q4 acquisition by Qiagen 2015-12-31
Mologen–Bâloise: investment, 201512 existing investor Bâloise Holding holding estimated 6% in Mologen 2015-12-31
Mologen–Deutsche Balaton: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Global Derivative Trading: investment, 201512 existing investor Global Derivative Trading GmbH owns estimated 24% in Mologen 2015-12-31
Mologen–Salvator Vermögensverwaltungs GmbH: investment, 201512 existing investor holding estimated 5% in Mologen 2015-12-31
Mologen–Signal Iduna: investment, 201512 existing investor Deutscher Ring Krankenversicherung holding estimated 6% in Mologen 2015-12-31
Boehringer–Polyphor: drug discovery, 201512 collab existent to identify + optimise drug candidates using macrocycle platform 2015-12-22
Effector Therapeutics–Abingworth: investment, 201512 financing round Series B totalling $40m incl returning investor Abingworth 2015-12-22
Effector Therapeutics–GSK: investment, 201512 financing round Series B totalling $40m incl returning investor SR One 2015-12-22
Effector Therapeutics–Novartis: investment, 201512 financing round Series B totalling $40m incl returning investor Novartis Venture Fund 2015-12-22
Effector Therapeutics–SEVERAL: investment, 201512 financing round Series B $40m led by Altitude Life Science Ventures 2015-12-22
Bayer–CRISPR Therapeutics: CRISPR technology, 201512– collab 50/50 joint venture w minimum of $300m r+d investment by Bayer in next 5 years 2015-12-21
Catherex–Amgen: investment, 201512 acquisition 100% for $10.5m upfront cash + milestones + royalties for Imlygic 2015-12-21
CRISPR Therapeutics–Bayer: investment, 201512– acquisition of minority stake for $35m by BLSC in connection with joint venture collaboration 2015-12-21
Sinphar Pharmaceutical–Medigene: EndoTAG-1, 201512–2016 acquisition of all EndoTAG assets by SynCore Biotechnology 2015-12-17
Xeltis–SEVERAL: investment, 201512 financing round Series B extension €3m bringing total Series B to €30m 2015-12-17
CRISPR Therapeutics–French Myopathy Association: gene therapy, 201512 collab onoging with Généthon 2015-12-16
Sophia Genetics–Alychlo: investment, 201512 financing round Series C totalling $15m incl lead investorAlychlo (Marc Coucke) 2015-12-16
next pagenext page 1 2 3 ... 18 19 20 ... 54 55 56  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top